Managing Valproate Therapy in Patients with End-Stage Renal Disease

Introduction to Valproate Dosing

• The American College of Emergency Physicians guidelines emphasize that valproate is effective for seizure control and status epilepticus prevention when dosed appropriately, with a recommended increase from 500 mg daily to at least 750-1000 mg daily (15-20 mg/kg/day range) for patients with end-stage renal disease (ESRD) and subtherapeutic valproate levels 1

Seizure Risk and Valproate Levels

• Subtherapeutic levels with breakthrough seizures carry substantial morbidity risk (injury, status epilepticus, sudden unexpected death in epilepsy), and the American College of Emergency Physicians guidelines support dose escalation to achieve therapeutic levels 2, 3

Alternative Therapies

• Levetiracetam may be a superior alternative to valproate in ESRD patients, as it is renally cleared with predictable dosing adjustments for dialysis and has been shown effective for myoclonus and seizures, according to the Annals of Emergency Medicine 3